- Home
- FFC vs CSTL Comparison
FFC vs CSTL Comparison
Compare FFC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- CSTL
- Stock Information
- Founded
- FFC 1983
- CSTL 2007
- Country
- FFC United States
- CSTL United States
- Employees
- FFC N/A
- CSTL N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- FFC Finance
- CSTL Health Care
- Exchange
- FFC Nasdaq
- CSTL Nasdaq
- Market Cap
- FFC 768.4M
- CSTL 848.1M
- IPO Year
- FFC N/A
- CSTL 2019
- Fundamental
- Price
- FFC $16.05
- CSTL $25.75
- Analyst Decision
- FFC
- CSTL Strong Buy
- Analyst Count
- FFC 0
- CSTL 6
- Target Price
- FFC N/A
- CSTL $40.33
- AVG Volume (30 Days)
- FFC 164.1K
- CSTL 358.8K
- Earning Date
- FFC 01-01-0001
- CSTL 02-27-2025
- Dividend Yield
- FFC 6.79%
- CSTL N/A
- EPS Growth
- FFC N/A
- CSTL N/A
- EPS
- FFC N/A
- CSTL 0.21
- Revenue
- FFC N/A
- CSTL $311,878,000.00
- Revenue This Year
- FFC N/A
- CSTL $51.99
- Revenue Next Year
- FFC N/A
- CSTL N/A
- P/E Ratio
- FFC N/A
- CSTL $122.41
- Revenue Growth
- FFC N/A
- CSTL 62.43
- 52 Week Low
- FFC $11.90
- CSTL $16.97
- 52 Week High
- FFC $14.96
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- FFC 54.43
- CSTL 37.34
- Support Level
- FFC $15.88
- CSTL $26.65
- Resistance Level
- FFC $16.28
- CSTL $28.48
- Average True Range (ATR)
- FFC 0.14
- CSTL 1.12
- MACD
- FFC 0.01
- CSTL -0.17
- Stochastic Oscillator
- FFC 51.06
- CSTL 0.94
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.